Skip to content
Back to the Guavy Wire
Stocks

Merck Licenses KRAS G12D Inhibitor SPR2015 for $400M Upfront

Instruments
MRK
Share

Pharmaceutical giant Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics Co., Ltd. for the investigational preclinical oral KRAS G12D inhibitor SPR2015.

The Wire

Read the full article for free.

A free account opens the rest of this article, how it scored, and the full Wire stream. No card required.

No spam. Unsubscribe anytime.